Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in

BACKGROUND The Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study addressed prognostic factors and the effects of concomitant treatment and glycometabolic control in diabetic patients with myocardial infarction (AMI). METHODS AND RESULTS Of 620 diabetic patients with AMI, 306 were randomly assigned to a >/=24-hour insulin-glucose infusion followed by multidose subcutaneous insulin. Three hundred fourteen patients were randomized as controls, receiving routine antidiabetic therapy. Thrombolysis and beta-blockers were administered when possible. Univariate and multivariate statistical analyses were applied to study predictors of long-term mortality. During an average follow-up of 3.4 years (range, 1.6 to 5.6 years), 102 patients (33%) in the intensive insulin group and 138 (44%) in the control group died (P=0. 011). Old age, previous heart failure, diabetes duration, admission blood glucose, and admission Hb AIc were independent predictors of mortality in the total cohort, whereas previous AMI, hypertension, smoking, or female sex did not add independent predictive value. Metabolic control, mirrored by blood glucose and Hb AIc, improved significantly more in patients on intensive insulin treatment than in the control group. beta-Blockers improved survival in control subjects, whereas thrombolysis was most efficient in the intensive insulin group. CONCLUSIONS Mortality in diabetic patients with AMI is predicted by age, previous heart failure, and severity of the glycometabolic state at admission but not by conventional risk factors or sex. Intensive insulin treatment reduced long-term mortality despite high admission blood glucose and Hb AIc.

[1]  L. Piegas,et al.  Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial , 1998 .

[2]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[3]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[4]  L. Køber,et al.  Long-term prognosis after acute myocardial infarction in patients with a history of arterial hypertension , 1998 .

[5]  A. Maggioni,et al.  Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. , 1997, Circulation.

[6]  G. Riccardi,et al.  Insulin and Sulfonylurea Therapy in NIDDM Patients: Are the Effects on Lipoprotein Metabolism Different Even With Similar Blood Glucose Control? , 1997, Diabetes.

[7]  K. Malmberg Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[8]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[9]  R. Shemin,et al.  Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. , 1997, The Journal of thoracic and cardiovascular surgery.

[10]  R. Califf,et al.  Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. , 1996, Journal of the American College of Cardiology.

[11]  J Herlitz,et al.  Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. , 1996, European heart journal.

[12]  S. Fava,et al.  The Prognostic Value of Blood Glucose in Diabetic Patients with Acute Myocardial Infarction , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[13]  K. Svärdsudd,et al.  Long-Term Glycemic Control Relates to Mortality in Type II Diabetes , 1995, Diabetes Care.

[14]  J. López-Sendón,et al.  Influence of sex on the short-term outcome of elderly patients with a first acute myocardial infarction. , 1995, Circulation.

[15]  Alan C. Wilson,et al.  Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: A statewide study , 1995 .

[16]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[17]  R. Klein Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes , 1995, Diabetes Care.

[18]  M. Laakso,et al.  NIDDM and Its Metabolic Control Predict Coronary Heart Disease in Elderly Subjects , 1994, Diabetes.

[19]  D. Labarthe,et al.  The Relation of Diabetes to the Severity of Acute Myocardial Infarction and Post-Myocardial Infarction Survival in Mexican-Americans and Non-Hispanic Whites: The Corpus Christi Heart Project , 1994, Diabetes.

[20]  B. Davis,et al.  Uniformity of captopril benefit in the SAVE study : subgroup analysis , 1994 .

[21]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[22]  K. Mak,et al.  Fasting blood sugar level: a determinant for in-hospital outcome in patients with first myocardial infarction and without glucose intolerance. , 1993, Annals of the Academy of Medicine, Singapore.

[23]  R. Nesto,et al.  Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. , 1992, Journal of the American College of Cardiology.

[24]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[25]  F. Eberli,et al.  Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. , 1991, Circulation research.

[26]  M. Taskinen,et al.  Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM , 1990, Diabetes.

[27]  L. Muratori,et al.  Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. , 1989, The American journal of cardiology.

[28]  O. Frazier,et al.  Efficacy of metabolic support with glucose-insulin-potassium for left ventricular pump failure after aortocoronary bypass surgery. , 1989, Circulation.

[29]  L. Rydén,et al.  Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. , 1989, European heart journal.

[30]  P. Wilson,et al.  The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. , 1988, JAMA.

[31]  L. Rydén,et al.  Myocardial infarction in patients with diabetes mellitus. , 1988, European heart journal.

[32]  K. Kent,et al.  Metabolic support during coronary reperfusion. , 1987, American heart journal.

[33]  G. C. Cingolani β-Adrenergic Receptors and Adenylate Cyclase Activity in Diabetic Rat Fat Cells , 1986, Diabetes.

[34]  J. Yudkin,et al.  Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. , 1986, British medical journal.

[35]  G. E. Chiappe de Cingolani Beta-adrenergic receptors and adenylate cyclase activity in diabetic rat fat cells. , 1986, Diabetes.

[36]  W. Duckworth,et al.  Hormonal control of lipolysis in perifused adipocytes from diabetic rats. , 1985, Endocrinology.

[37]  J. Kjekshus Comments — Beta-blockers: Heart rate reduction a mechanism of benefit , 1985 .

[38]  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. , 1982, JAMA.

[39]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[40]  A. Liedtke Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. , 1981, Progress in cardiovascular diseases.

[41]  L. Opie,et al.  Propranolol and experimental myocardial infarction: substrate effects. , 1976, Postgraduate medical journal.

[42]  L. Opie Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. , 1975, The American journal of cardiology.

[43]  B. I. Gorokhovsky Myocardial infarction in patients with diabetes mellitus , 1969, Kazan medical journal.

[44]  C. Park,et al.  Regulation of glucose uptake in muscle. II. Rate-limiting steps and effects of insulin and anoxia in heart muscle from diabetic rats. , 1961, The Journal of biological chemistry.

[45]  P. W. Wilson,et al.  The Relation , 2009 .

[46]  D.,et al.  Regression Models and Life-Tables , 2022 .